Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the end of 2025 due to ...

Merck & Co on Tuesday announced job and cost cuts that it said will save $3 billion a year, after it posted lower ...

The Gardasil human papillomavirus virus vaccine remains Merck’s second best-selling drug behind cancer treatment Keytruda.

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed ...

In summary, Merck’s earnings call reflected a balanced outlook, with strong performances in key areas offset by significant challenges, particularly in China. The company’s forward-looking guidance ...

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster ...

China’s first domestically made nine-valent HPV vaccine, a direct competitor to Merck’s Gardasil 9, is being priced at 499 yuan ($70) per dose, the state-owned Xinhua News Agency reports.

Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...